Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
Diagn Mol Pathol ; 17(3): 127-33, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18382367

ABSTRACT

Microsatellite instability (MSI) is a characteristic molecular phenotype of tumors from the hereditary nonpolyposis colorectal cancer (Lynch) syndrome. Routine MSI screening of tumors in younger patients is an efficient prescreening tool for the population-based detection of Lynch syndrome in the absence of family cancer history. We describe here the optimization of a denaturing high performance liquid chromatography (DHPLC) assay for MSI analysis with the "Bethesda" panel of markers recommended by the National Cancer Institute and with a more recently proposed "pentaplex" panel of 5 mononucleotide repeat markers. By using various polymerase chain reaction primers and tumor DNA samples with known MSI status, each of the 3 standard DHPLC formats tested could correctly identify the MSI status without the "stutter peaks" inherent in the capillary electrophoresis (CE) methods that are currently in use. Dilution experiments showed that the detection limit for MSI using DHPLC was at least 1:100, thus avoiding the need for tumor enrichment by microdissection before analysis. Concordance between CE and DHPLC for the detection of instability in the Bethesda panel markers was 95%. Optimal DHPLC running conditions for the pentaplex mononucleotide panel are also described. In conclusion, DHPLC provides a sensitive and specific alternative for routine MSI analysis that is free of the stutter peaks observed with CE and which can be used with either the Bethesda or pentaplex mononucleotide marker panels.


Subject(s)
Biomarkers, Tumor/analysis , Chromatography, High Pressure Liquid/methods , Colorectal Neoplasms, Hereditary Nonpolyposis/genetics , Microsatellite Instability , Biomarkers, Tumor/genetics , Humans , Polymerase Chain Reaction
3.
Am J Clin Pathol ; 128(6): 994-1001, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18024325

ABSTRACT

Cribriform-morular variant (C-MV) of papillary thyroid carcinoma (PTC) is a rare and unusual neoplasm composed of multiple histologic components, including cribriform, papillary, solid, tall columnar, and morular patterns. Analyses of gross C-MV of PTC lesions has linked adenomatous polyposis coli (APC) mutations to its pathogenesis; however, the extent of involvement of mutations in the development of individual components is unclear. We report on bidirectional sequencing of the mutation cluster region (codons 1032-1565) of the APC gene in individually laser-microdissected components of a previously unreported C-MV of PTC. A silent Thr1493Thr gene variant was found in all tumoral components, whereas a 5-base-pair frameshift deletion at codon 1309 was identified only in the morules. Neither variant was observed in matched normal thyroid tissue. These results show the histologic components of C-MV of PTC to have some common mutational background, although additional somatic mutations may be involved in the development of morular structures.


Subject(s)
Adenocarcinoma, Papillary/genetics , Genes, APC , Microdissection/methods , Thyroid Neoplasms/genetics , Adenocarcinoma, Papillary/pathology , Adenocarcinoma, Papillary/surgery , Adult , Base Sequence , Clone Cells , DNA Mutational Analysis , DNA, Neoplasm/analysis , Female , Humans , Lasers , Molecular Sequence Data , Thyroid Neoplasms/pathology , Thyroid Neoplasms/surgery
4.
Clin Chem ; 53(1): 62-70, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17110474

ABSTRACT

BACKGROUND: Epidermal growth factor receptor gene (EGFR) variants may be useful markers for identifying responders to gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors of EGFR; therefore, sensitive and cost-effective assays are needed to detect EGFR variants in routine clinical samples. We have developed a partially denaturing HPLC (pDHPLC) assay that is superior to direct sequencing with respect to detection limits, costs, and time requirements. METHODS: Primers, temperatures, and buffer conditions were optimized for PCR-pDHPLC analysis of EGFR exons 18-21. We evaluated the detection limits of pDHPLC and direct sequencing by analyzing mixtures of wild-type and variant EGFR DNA and screened 192 lung cancer samples to examine the diversity of pDHPLC-detectable variants. To assess amenability to routine analysis, we tested lung and pleural tissue specimens from 14 lung cancer patients treated with gefitinib. RESULTS: The detection limits for variant alleles were 1:100 for pDHPLC and 1:5 for direct sequencing. pDHPLC analysis detected 26 unique EGFR variants, including the common deletions in exon 19 and substitutions in codons 787 and 858. Direct sequencing could not identify 30% (18 of 60) of the variant amplicons identified by pDHPLC. We identified these 18 amplicons by fraction collection after pDHPLC analysis. Analysis of a limited series of lung biopsy samples detected EGFR variants more frequently in gefitinib responders than in nonresponders. pDHPLC analysis was 56% less expensive and 39% faster than direct sequencing. CONCLUSIONS: pDHPLC-based analysis detects EGFR variations in routine clinical samples with a better detection limit and lower cost and time requirement than direct sequencing.


Subject(s)
ErbB Receptors/genetics , Lung Neoplasms/genetics , Antineoplastic Agents/therapeutic use , Biopsy , Chromatography, High Pressure Liquid/economics , Codon , ErbB Receptors/antagonists & inhibitors , Exons , Gefitinib , Humans , Lung Neoplasms/drug therapy , Mutation , Polymerase Chain Reaction/economics , Quinazolines/therapeutic use , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...